Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.22.4
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Operating expenses:      
Research and development (including related party purchases of $1,600, $2,339 and $1,249 for the years ended December 31, 2022, 2021, and 2020 respectively) $ 296,281 $ 197,568 $ 108,741
Selling, general and administrative (including related party purchases of $360, $533 and $220 for the years ended December 31, 2022, 2021 and 2020 respectively) 95,922 61,521 23,495
Total operating expenses 392,203 259,089 132,236
Loss from operations (392,203) (259,089) (132,236)
Interest and other income, net 16,905 1,148 5,649
Interest expense (118) (2,426) (249)
Income from equity method investment 19,463 29,405 5,799
Transaction expenses related to merger 0 (9,087) 0
Gain on deconsolidation of subsidiary 0 0 6,904
Gain from change in fair value of warrants and earnout shares 98,002 49,853 0
Convertible note extinguishment loss 0 (665) 0
Total other income, net 134,252 68,228 18,103
Loss before income taxes (257,951) (190,861) (114,133)
Income tax expense (benefit) 92 (10,537) 31
Net loss $ (258,043) $ (180,324) $ (114,164)
Net loss per share, basic (in dollars per share) $ (0.44) $ (0.61) $ (1.10)
Net loss per share, diluted (in dollars per share) $ (0.44) $ (0.61) $ (1.10)
Weighted-average common shares outstanding, basic (in shares) 585,544,043 294,851,732 103,946,993
Weighted-average common shares outstanding, diluted (in shares) 585,544,043 294,851,732 103,946,993